Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mulè, Antonino
AMELIORATE, NCT04174612 / 2019-003936-21: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting
3
172
Europe
Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD
Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Acute Myeloid Leukemia With FLT3/ITD Mutation
12/22
08/25
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Recruiting
3
339
Europe, RoW
High intensity therapies, Low intensity therapies
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX
Acute Myeloid Leukemia, Relapse/Recurrence
01/28
01/28
ALL2418, NCT03610438 / 2018-003006-32: Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Recruiting
2a
76
Europe
Inotuzumab Ozogamicin (IO)
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoid Leukemia
11/22
11/22
NCT05306301 / 2022-000633-17: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Recruiting
2
32
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA
Chemotherapy, Leukemia, Acute Lymphoblastic
02/25
07/28
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting
N/A
4000
Europe
Registration into the STREAM platform
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
07/32
07/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mulè, Antonino
AMELIORATE, NCT04174612 / 2019-003936-21: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting
3
172
Europe
Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD
Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Acute Myeloid Leukemia With FLT3/ITD Mutation
12/22
08/25
NCT04168502 / 2019-003871-20: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Acute Myeloid Leukemia
04/25
04/27
IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Recruiting
3
339
Europe, RoW
High intensity therapies, Low intensity therapies
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX
Acute Myeloid Leukemia, Relapse/Recurrence
01/28
01/28
ALL2418, NCT03610438 / 2018-003006-32: Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Recruiting
2a
76
Europe
Inotuzumab Ozogamicin (IO)
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoid Leukemia
11/22
11/22
NCT05306301 / 2022-000633-17: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Recruiting
2
32
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA
Chemotherapy, Leukemia, Acute Lymphoblastic
02/25
07/28
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting
N/A
4000
Europe
Registration into the STREAM platform
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
07/32
07/32

Download Options